Real-world outcomes of anti-vascular endothelial growth factor therapy for retinal vascular vein occlusion in Tibet,China

作     者：Xue-Mei Zhu Ying-Ying Yu Sina Zhuoga Xiao Dawa Yong-Kang Zhou Ouzhu Wangmu Deji Yangzong Fang An Heng Miao Ming-Wei Zhao 

作者机构：Department of Ophthalmology&Clinical Centre of OptometryPeking University People's HospitalEye Diseases and Optometry InstituteBeijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid DiseasesCollege of OptometryPeking University Health Science CenterBeijing 100044China Department of OphthalmologyTibet Autonomous Region People's HospitalLhasa 850010Tibet Autonomous RegionChina 

出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)

年 卷 期：2022年第15卷第11期

页      面：1814-1820页

核心收录：

学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学] 

基　　金：Supported by Beijing Bethune Charitable Foundation (No.BJ-LM2019003J,No.BJ2021IIT006) Tibet Natural Science Funding Committee Grant (No.2019ZR-ZY21) 

主　　题：anti-vascular endothelial growth factor therapy macular edema retinal venous occlusive disease intravitreal visual acuity Tibet 

摘      要：AIM: To evaluate the outcomes of intravitreal antivascular endothelial growth factor(anti-VEGF) agents for patients with retinal vein occlusion(RVO) related-macular edema(ME) in ***: A retrospective, observational, single-center study. The demographic and clinical data of 90 RVO Tibetan patients(93 eyes) treated with either ranibizumab or conbercept in Tibet Autonomous Region People’s Hospital from Jan 2018 to December 2019 were ***: The mean patient age was 56.8±10.6y, 45(50%) of them were female. The mean living altitude was 3867.8±567.9 m. At the last visit, the best-corrected visual acuity(BCVA) significantly increased(52.2±21.8 letters) in comparison with the baseline(38.2±24.1 letters, P0.001);while the central retinal thickness(CRT) significantly reduced(245.5±147.6 μm) in comparison with the baseline(504.1±165.2 μm, P0.001). The 43.0% of the eyes gained≥15 letters, 60.2% of the eyes gained ≥10 letters, and 78.5% of the eyes gained ≥5 letters. No vision loss was noted in 92.5% of the eyes, 4 eyes lost more than 10 letters during follow-up period. The mean number of injections was 2.4±1.8. No severe ocular or systemic adverse events related to either the drug or injection were ***: Anti-VEGF therapy is effective and safe in Tibetan patients for the treatment of RVO related ME.